Mephenytoin
From Wikipedia, the free encyclopedia
Mephenytoin
|
|
Systematic (IUPAC) name | |
5-ethyl-3-methyl-5-phenyl-imidazolidine-2,4-dione | |
Identifiers | |
CAS number | 50-12-4 |
ATC code | N03AB04 |
PubChem | 4060 |
DrugBank | APRD00512 |
Chemical data | |
Formula | C12H14N2O2 |
Mol. weight | 218.256 |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | 7 hours |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
C (USA) |
Legal status | |
Routes | Oral |
Mephenytoin (marketed as Mesantoin® by Novartis) is a hydantoin, used as an anticonvulsant. It was introduced approximately 10 years after phenytoin, in the late 1940s. The significant metabolite of mephenytoin is nirvanol (5-ethyl-5-phenylhydantoin), which was the first hydantoin (briefly used as a hypnotic). However, nirvanol is quite toxic and mephenytoin was only considered after other less toxic anticonvulsants had failed. It can cause potentially fatal blood dyscrasia in 1% of patients.
Mephenytoin is no longer available in the US or the UK. It is still studied largely because of its interesting hydroxylation polymorphism.
[edit] References
- The Treatment of Epilepsy edited by S. D. Shorvon, David R. Fish, Emilio Perucca, W. Edwin Dodson. Blackwell Publishing. 2004. ISBN 0-632-06046-8
- The Medical Treatment of Epilepsy by Stanley R Resor. Published by Marcel Dekker (1991). ISBN 0-8247-8549-5.
- The Comparative Toxicogenomics Database: Mephenytoin